These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 25180798)
1. A generalized estimating equation approach to analysis of maintenance of wakefulness testing in a study of lisdexamfetamine dimesylate, armodafinil, and placebo in sleep-deprived adults. Roth T; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Gasior M J Clin Psychopharmacol; 2014 Oct; 34(5):642-4. PubMed ID: 25180798 [TBL] [Abstract][Full Text] [Related]
2. Maintenance of wakefulness with lisdexamfetamine dimesylate, compared with placebo and armodafinil in healthy adult males undergoing acute sleep loss. Gasior M; Freeman J; Zammit G; Donnelly P; Gao J; Ferreira-Cornwell MC; Roth T J Clin Psychopharmacol; 2014 Dec; 34(6):690-6. PubMed ID: 25159886 [TBL] [Abstract][Full Text] [Related]
3. Effects of armodafinil in the treatment of residual excessive sleepiness associated with obstructive sleep apnea/hypopnea syndrome: a 12-week, multicenter, double-blind, randomized, placebo-controlled study in nCPAP-adherent adults. Roth T; White D; Schmidt-Nowara W; Wesnes KA; Niebler G; Arora S; Black J Clin Ther; 2006 May; 28(5):689-706. PubMed ID: 16861091 [TBL] [Abstract][Full Text] [Related]
4. Pharmacodynamic effects on alertness of single doses of armodafinil in healthy subjects during a nocturnal period of acute sleep loss. Dinges DF; Arora S; Darwish M; Niebler GE Curr Med Res Opin; 2006 Jan; 22(1):159-67. PubMed ID: 16393442 [TBL] [Abstract][Full Text] [Related]
5. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder: randomized withdrawal design. Brams M; Weisler R; Findling RL; Gasior M; Hamdani M; Ferreira-Cornwell MC; Squires L J Clin Psychiatry; 2012 Jul; 73(7):977-83. PubMed ID: 22780921 [TBL] [Abstract][Full Text] [Related]
6. A phase 1, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetics of single and multiple doses of lisdexamfetamine dimesylate in Japanese and Caucasian healthy adult subjects. Ermer J; Martin P; Corcoran M; Matsuo Y Neuropsychopharmacol Rep; 2020 Mar; 40(1):16-29. PubMed ID: 31765110 [TBL] [Abstract][Full Text] [Related]
7. Effects of dextroamphetamine, caffeine and modafinil on psychomotor vigilance test performance after 44 h of continuous wakefulness. Killgore WD; Rupp TL; Grugle NL; Reichardt RM; Lipizzi EL; Balkin TJ J Sleep Res; 2008 Sep; 17(3):309-21. PubMed ID: 18522689 [TBL] [Abstract][Full Text] [Related]
8. Adjunct armodafinil improves wakefulness and memory in obstructive sleep apnea/hypopnea syndrome. Hirshkowitz M; Black JE; Wesnes K; Niebler G; Arora S; Roth T Respir Med; 2007 Mar; 101(3):616-27. PubMed ID: 16908126 [TBL] [Abstract][Full Text] [Related]
9. Acute effects of lisdexamfetamine and D-amphetamine on social cognition and cognitive performance in a placebo-controlled study in healthy subjects. Dolder PC; Strajhar P; Vizeli P; Odermatt A; Liechti ME Psychopharmacology (Berl); 2018 May; 235(5):1389-1402. PubMed ID: 29511807 [TBL] [Abstract][Full Text] [Related]
10. Effects of lisdexamfetamine on plasma steroid concentrations compared with d-amphetamine in healthy subjects: A randomized, double-blind, placebo-controlled study. Strajhar P; Vizeli P; Patt M; Dolder PC; Kratschmar DV; Liechti ME; Odermatt A J Steroid Biochem Mol Biol; 2019 Feb; 186():212-225. PubMed ID: 30381248 [TBL] [Abstract][Full Text] [Related]
11. Lisdexamfetamine dimesylate in adults with attention-deficit/ hyperactivity disorder who report clinically significant impairment in executive function: results from a randomized, double-blind, placebo-controlled study. Adler LA; Dirks B; Deas PF; Raychaudhuri A; Dauphin MR; Lasser RA; Weisler RH J Clin Psychiatry; 2013 Jul; 74(7):694-702. PubMed ID: 23945447 [TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Harsh JR; Hayduk R; Rosenberg R; Wesnes KA; Walsh JK; Arora S; Niebler GE; Roth T Curr Med Res Opin; 2006 Apr; 22(4):761-74. PubMed ID: 16684437 [TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial of the efficacy and safety of lisdexamfetamine dimesylate as augmentation therapy in adults with residual symptoms of major depressive disorder after treatment with escitalopram. Trivedi MH; Cutler AJ; Richards C; Lasser R; Geibel BB; Gao J; Sambunaris A; Patkar AA J Clin Psychiatry; 2013 Aug; 74(8):802-9. PubMed ID: 24021497 [TBL] [Abstract][Full Text] [Related]
14. Armodafinil, the R-enantiomer of modafinil: wake-promoting effects and pharmacokinetic profile in the rat. Wisor JP; Dement WC; Aimone L; Williams M; Bozyczko-Coyne D Pharmacol Biochem Behav; 2006 Nov; 85(3):492-9. PubMed ID: 17134745 [TBL] [Abstract][Full Text] [Related]
15. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. Adler LA; Weisler RH; Goodman DW; Hamdani M; Niebler GE J Clin Psychiatry; 2009 Dec; 70(12):1652-61. PubMed ID: 20141706 [TBL] [Abstract][Full Text] [Related]
16. Armodafinil and modafinil in patients with excessive sleepiness associated with shift work disorder: a pharmacokinetic/pharmacodynamic model for predicting and comparing their concentration-effect relationships. Darwish M; Bond M; Ezzet F J Clin Pharmacol; 2012 Sep; 52(9):1328-42. PubMed ID: 22039290 [TBL] [Abstract][Full Text] [Related]
17. A double-blind, placebo-controlled study of armodafinil for excessive sleepiness in patients with treated obstructive sleep apnea and comorbid depression. Krystal AD; Harsh JR; Yang R; Rippon GA; Lankford DA J Clin Psychiatry; 2010 Jan; 71(1):32-40. PubMed ID: 20051221 [TBL] [Abstract][Full Text] [Related]
18. Modafinil reduces microsleep during partial sleep deprivation in depressed patients. Beck J; Hemmeter U; Brand S; Muheim F; Hatzinger M; Holsboer-Trachsler E J Psychiatr Res; 2010 Oct; 44(13):853-64. PubMed ID: 20171656 [TBL] [Abstract][Full Text] [Related]
19. Effects of open-label lisdexamfetamine dimesylate on self-reported quality of life in adults with ADHD. Brams M; Giblin J; Gasior M; Gao J; Wigal T Postgrad Med; 2011 May; 123(3):99-108. PubMed ID: 21566420 [TBL] [Abstract][Full Text] [Related]